Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Nektar Therapeutics sell kalki

Start price
€21.14
11.07.20 / 50%
Target price
-
04.11.21
Performance (%)
-9.58%
End price
€19.11
14.03.21
Summary
This prediction ended on 14.03.21 with a price of €19.11. With a performance of -9.58%, the SELL prediction for Nektar Therapeutics by kalki was down slightly. kalki has 50% into this prediction

Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.

Performance without dividends (%)
Name 1w 1m 1y 3y
Nektar Therapeutics 2.114% 2.114% 29.821% -94.979%
iShares Core DAX® 1.883% 5.122% 21.667% 22.437%
iShares Nasdaq 100 0.125% 2.574% 45.951% 55.507%
iShares Nikkei 225® -0.201% 4.341% 28.806% 9.945%
iShares S&P 500 0.728% 4.141% 34.630% 50.086%

Comments by kalki for this prediction

In the thread Discuss Nektar Therapeutics

Sell Nektar Therapeutics